AstraZeneca PLC
AZN
$192.39
-$0.11-0.06%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.11% | 11.99% | 11.74% | 7.17% | 23.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.11% | 11.99% | 11.74% | 7.17% | 23.84% |
| Cost of Revenue | 47.03% | -9.38% | 16.86% | 0.68% | 3.65% |
| Gross Profit | -3.16% | 18.27% | 10.70% | 8.55% | 28.07% |
| SG&A Expenses | 18.86% | -1.74% | -1.52% | -1.21% | 18.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 239.47% | -256.00% | -20.00% | -70.15% | 45.71% |
| Total Operating Expenses | 22.43% | 0.61% | 7.63% | 2.38% | 14.35% |
| Operating Income | -32.55% | 73.88% | 26.98% | 21.86% | 48.52% |
| Income Before Tax | 57.80% | 77.46% | 30.45% | 21.50% | 85.73% |
| Income Tax Expenses | 80.72% | 79.49% | 44.78% | -22.42% | 367.74% |
| Earnings from Continuing Operations | 55.27% | 76.90% | 26.97% | 33.99% | 56.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 50.00% | 300.00% | -400.00% | -100.00% |
| Net Income | 55.07% | 77.26% | 27.14% | 33.82% | 56.25% |
| EBIT | -32.55% | 73.88% | 26.98% | 21.86% | 48.52% |
| EBITDA | -21.64% | 32.83% | 21.14% | 16.25% | 24.00% |
| EPS Basic | 54.98% | 77.15% | 27.06% | 33.74% | 56.13% |
| Normalized Basic EPS | -34.46% | 82.14% | 29.72% | 25.56% | 52.41% |
| EPS Diluted | 53.94% | 78.02% | 27.63% | 33.57% | 56.70% |
| Normalized Diluted EPS | -34.46% | 82.36% | 29.88% | 25.56% | 52.42% |
| Average Basic Shares Outstanding | 0.06% | 0.06% | 0.06% | 0.06% | 0.06% |
| Average Diluted Shares Outstanding | 0.06% | -0.06% | -0.06% | 0.06% | 0.06% |
| Dividend Per Share | 3.33% | -- | 3.00% | -- | 6.60% |
| Payout Ratio | -- | -0.42% | -0.54% | -0.18% | -- |